- Home
- FOLD vs HHH Comparison
FOLD vs HHH Comparison
Compare FOLD & HHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- HHH
- Stock Information
- Founded
- FOLD 2002
- HHH 2010
- Country
- FOLD United States
- HHH United States
- Employees
- FOLD N/A
- HHH N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- HHH Real Estate Investment Trusts
- Sector
- FOLD Health Care
- HHH Real Estate
- Exchange
- FOLD Nasdaq
- HHH Nasdaq
- Market Cap
- FOLD 2.9B
- HHH 3.3B
- IPO Year
- FOLD 2007
- HHH N/A
- Fundamental
- Price
- FOLD $6.83
- HHH $66.35
- Analyst Decision
- FOLD Strong Buy
- HHH Strong Buy
- Analyst Count
- FOLD 9
- HHH 2
- Target Price
- FOLD $17.00
- HHH $82.00
- AVG Volume (30 Days)
- FOLD 3.9M
- HHH 304.8K
- Earning Date
- FOLD 05-08-2025
- HHH 05-07-2025
- Dividend Yield
- FOLD N/A
- HHH 5.29%
- EPS Growth
- FOLD N/A
- HHH N/A
- EPS
- FOLD N/A
- HHH 3.96
- Revenue
- FOLD $528,294,999.00
- HHH $1,750,689,000.00
- Revenue This Year
- FOLD $21.83
- HHH N/A
- Revenue Next Year
- FOLD $22.16
- HHH $45.83
- P/E Ratio
- FOLD N/A
- HHH $11.58
- Revenue Growth
- FOLD 32.29
- HHH 92.65
- 52 Week Low
- FOLD $6.20
- HHH $56.24
- 52 Week High
- FOLD $12.65
- HHH $87.77
- Technical
- Relative Strength Index (RSI)
- FOLD 32.01
- HHH 39.32
- Support Level
- FOLD $6.20
- HHH $64.95
- Resistance Level
- FOLD $6.95
- HHH $66.82
- Average True Range (ATR)
- FOLD 0.43
- HHH 3.10
- MACD
- FOLD -0.04
- HHH -0.28
- Stochastic Oscillator
- FOLD 29.86
- HHH 35.77
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
About HHH Howard Hughes Holdings Inc.
Howard Hughes Holdings Inc owns, manages, and develops commercial, residential, and mixed-use real estate throughout the USA. Its portfolio is strategically positioned to meet and accelerate development based on market demand, resulting in one of the strongest real estate platforms in the country. It operates through four business segments: Operating Assets, MPCs, Strategic Developments and Seaport.